insights_auto
Why is CTSO down 2.50%?
Dive Deeperchevron_right
CTSO:NASDAQ
Cytosorbents Corp
$3.90
arrow_downward
-2.50%(-0.100) 1D
Sep 30, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CTSO...
Open
$4.13
High
$4.15
Low
$3.76
Mkt. cap
12.29M
Avg. vol.
287.93K
Volume
3.00
52-wk high
$20.40
52-wk low
$3.76
EPS
-$5.80
Beta
1.34
Shares outstanding
3.15M
No. of employees
129
Open
$4.13
High
$4.15
Low
$3.76
Mkt. cap
12.29M
Avg. vol.
287.93K
Volume
3.00
52-wk high
$20.40
52-wk low
$3.76
EPS
-$5.80
Beta
1.34
Shares outstanding
3.15M
No. of employees
129
News stories
From web sources and news partners
markets.businessinsider.com
·
11 minutes ago
Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026
PR Newswire
·
18 minutes ago
Kroger Launches Mastercard Powered by Payments Platform Imprint: NYSE Content Update
Business Wire
·
58 minutes ago
Faraday Future and FF EAI Robotics Ecosystem Inc. (Nasdaq: FFR) Jointly Address Key Investor Questions Regarding the Proposed Combination of FFAI's Robotics Business
Seeking Alpha
·
43 minutes ago
AI talk is nearly universal on S&P 500 calls, but the payoff still isn’t, Apollo says
Profile
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
About Cytosorbents Corp